The Cell Therapy Manufacturing Market is estimated to be valued at US$ 12.99 Mn in 2023 and is expected to exhibit a CAGR of 15 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Cell therapy manufacturing involves isolation, purification, and culture of human cells for therapeutic use. The growing prevalence of chronic diseases has boosted the demand for advanced cell-based therapies. Cell therapy manufacturing helps develop personalized therapies that can be produced on large scale. Key advantages include high specificity, minimal side effects, and improved therapeutic efficacy.
Market key trends:
One of the key trends driving the cell therapy manufacturing market size is development of state-of-the-art cell therapy manufacturing facilities. Several major players are focusing on expanding their manufacturing capabilities by setting up advanced facilities to meet growing demand. For instance, WuXi AppTec, Inc. has established a new manufacturing facility in Philadelphia, US with end-to-end fully-integrated R&D and manufacturing capabilities for cell therapies. Moreover, increasing use of advanced technologies such as cell culturing technologies, single-use bioprocessing infrastructure and digitization tools in therapy manufacturing is fueling market growth. Adoption of advanced technologies helps improve efficiency, standardization and lower manufacturing costs.
Porter’s Analysis
Threat of new entrants: The large capital requirements and stringent regulatory norms act as a barrier for new players in the market. However, the growing market size provides opportunities.
Bargaining power of buyers: The presence of many players in the market gives buyers more options to choose from. This increases their bargaining power.
Bargaining power of suppliers: Suppliers of raw materials and manufacturing equipment have some bargaining power due to a limited number of major players.
Threat of new substitutes: There are limited direct substitutes due to advances in cell and genetic therapies.
Competitive rivalry: High as players compete on manufacturing capacities, quality, and technological innovation.
SWOT Analysis
Strength: The growing demand for cell therapies in various therapeutic areas like oncology, cardiology presents major growth opportunities.
Weakness: High costs associated with R&D, equipment, and stringent regulatory approvals are challenges faced. Manufacturing complex cell therapies requires specialized facilities and expertise.
Opportunity: Regional expansion into high growth markets and collaboration with pharmaceutical players to diversify revenue sources can be opportunities.
Threats: Supply and production bottlenecks, risk of contamination, and regulatory changes pose challenges.
Key Takeaways
The global cell therapy manufacturing market is expected to witness high growth at a CAGR of 15% over the forecast period, due to increasing prevalence of chronic diseases and demand for regenerative medicines.
The market is dominated by North America currently due to presence of major players and high healthcare spending. Asia Pacific is expected to grow at the fastest pace due to increasing initiatives to develop domestic cell therapy industries, lower costs, and large patient population.
Key players operating in the cell therapy manufacturing market are WuXi AppTec, Inc., Lineage Cell Therapeutics, Inc., HEALIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc. These players are focusing on expanding manufacturing capacities and capabilities through partnerships and acquisitions.
Get more insights on this topic: https://www.trendingwebwire.com/cell-therapy-manufacturing-market-size-and-opportunity-analysis/
Explore more information, Please visit: https://www.newsintv.com/news/offshore-the-decommissioning-a-best-growing-sector/
